Pharming Group (NASDAQ:PHAR) Sees Large Volume Increase – Here’s What Happened

Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) saw an uptick in trading volume on Wednesday . Approximately 54,371 shares traded hands during trading, an increase of 186% from the previous session’s volume of 19,016 shares.The stock last traded at $10.54 and had previously closed at $10.55.

Analyst Ratings Changes

Several research firms recently weighed in on PHAR. Weiss Ratings restated a “sell (d)” rating on shares of Pharming Group in a research report on Friday, August 7th. HC Wainwright reiterated a “buy” rating and issued a $37.00 price objective on shares of Pharming Group in a report on Monday. Oppenheimer reiterated an “outperform” rating on shares of Pharming Group in a research note on Thursday, July 30th. Canaccord Genuity Group increased their target price on Pharming Group from $37.00 to $38.00 and gave the company a “buy” rating in a report on Monday, August 3rd. Finally, Zacks Research downgraded Pharming Group from a “hold” rating to a “strong sell” rating in a research report on Friday, July 31st. Three analysts have rated the stock with a Buy rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $38.67.

Pharming Group Price Performance

The stock’s fifty day moving average price is $11.78 and its 200-day moving average price is $13.67. The firm has a market cap of $763.01 million, a PE ratio of 89.83 and a beta of 0.01. The company has a debt-to-equity ratio of 0.34, a current ratio of 3.01 and a quick ratio of 2.31.

Pharming Group (NASDAQ:PHAR) last posted its quarterly earnings results on Thursday, July 30th. The company reported $0.02 earnings per share for the quarter, missing the consensus estimate of $0.06 by ($0.04). Pharming Group had a return on equity of 3.40% and a net margin of 2.51%. As a group, equities analysts expect that Pharming Group N.V. Sponsored ADR will post 0.22 EPS for the current fiscal year.

Pharming Group Company Profile

Pharming Group N.V. is a biopharmaceutical company headquartered in Leiden, the Netherlands, focused on developing and commercializing treatments for rare diseases. The company uses its expertise in protein replacement therapies and other biotechnology platforms to address conditions with limited treatment options.

Pharming’s principal product is Ruconest (conestat alfa), a recombinant human C1 esterase inhibitor used to treat acute attacks of hereditary angioedema, a rare genetic disorder that can cause severe swelling.